No profile data available.
ThermoGenesis Holdings, Inc. (THMO) is a healthcare company in the additional specific healthcare equipment industry, based in Rancho Cordova, United States, with about 25 full-time employees.
It reported revenue of $9.45 million for fiscal year 2023, down 9.9% from fiscal year 2022, and net income of -$17.98 million. In Q1 2024 (the quarter ended March 31, 2024) revenue was $2.74 million, up 6.4% from a year before. Its largest business segment, Device Revenue, brought in 71% of segment revenue in fiscal year 2023. Its market capitalization was $1,584 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of October 8, 2026.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing.
ThermoGenesis reported $9.45 million in revenue for fiscal year 2023, down 9.9% from $10.48 million in fiscal year 2022. In Q1 2024 revenue was $2.74 million.
Device Revenue, with $6.86 million or 71% of segment revenue in fiscal year 2023. Next: Service (19%) and Exclusivity Fee (8%).
$1,584 as of October 8, 2026.
Listed companies of a similar size in the same industry (additional specific healthcare equipment) include Wellness Center Usa, Inc. (WCUI), Remedent, Inc. (REMI), Biolase Inc (BIOLQ).